Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

Dexcom stock surged Thursday after the Food and Drug Administration cleared its newest diabetes device for an extended 15-day ...

Nanowear announced that it entered into a partnership with Dexcom to ingest glucose data from its latest continuous glucose ...

In a new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day Dexcom G7 integrated continuous glucose monitor (CGM) in ...

The Dexcom 15-day G7 continuous glucose monitor (CGM) is accurate and safe for use up to 15.5 days in adults with diabetes. Currently under review by the US Food and Drug Administration ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025.

The San Diego-based medical device company stated that the Dexcom G7 15 Day has an overall Mean Absolute Relative Difference (MARD) of 8.0%, showcasing its precision in glucose level readings. The ...

"We conclude that the Dexcom 15-day G7 CGM is accurate and safe for use up to 15.5 days in adults with diabetes with a 27-minute warm-up," stated the investigators.